LSU Healthcare Network / Metairie Multi-Specialty Clinic

Summary

LSU Healthcare Network / Metairie Multi-Specialty Clinic is a medical facility located in Metairie, Louisiana. This center is recognized for care of Prostate Cancer, Bladder Cancer, Kidney Cancer, Renal Cell Carcinoma, Prostate Adenocarcinoma and other specialties. LSU Healthcare Network / Metairie Multi-Specialty Clinic is involved with conducting 39 clinical trials across 136 conditions. There are 7 research doctors associated with this hospital, such as Scott E. Delacroix, Augusto C. Ochoa, Amelia Jernigan, MD, and Rajasree P. Chowdry.

Top PIs

Clinical Trials running at LSU Healthcare Network / Metairie Multi-Specialty Clinic

Prostate Cancer

Bladder Cancer

Kidney Cancer

Bladder Carcinoma

Ovarian Cancer

Uterine Cancer

Prostate Adenocarcinoma

Renal Cell Carcinoma

Cancer

Urethral Cancer

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Recruiting

2 awards

Phase 3

30 criteria

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3

Carboplatin Before Surgery

for Prostate Cancer

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with high-risk prostate cancer with BRCA1 and BRCA2 gene mutations.

Recruiting

1 award

Phase 2

10 criteria